{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"22.3","value":"12.5"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"12.4","value":"5.1"}]}],"title":"100 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"22.3","value":"12.5"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"12.4","value":"5.1"}]}],"title":"180 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"22.3","value":"12.5"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"12.4","value":"5.1"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Clinically active HHV-6 infection (e.g. symptoms, cytopenias) or HHV-6 viremia without viral load decline 0.5 log after 2 weeks of therapy). A cumulative incidence will be computed along with a 90% CI.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"100 days, 180 days, 365 days","title":"Cumulative Incidences of Viral Reactivations and Infections: Grade 2 HHV-6 Infection","type":"SECONDARY","unitOfMeasure":"percentage of participants"}